Nov. 19, 2014, 1:16 PM
- Thinly-traded nano cap Cynapsus Therapeutics (OTCQX:CYNAF +23.4%) jumps on turnover of 1.6M shares in response to its announcement of positive top-line results from a Phase 2 clinical trial evaluating APL-130277 for the management of OFF motor symptoms in patients with Parkinson's disease (PD).
- APL-130277 is a fast-acting sublingual thin filmstrip of apomorphine. An OFF episode is a complication of PD that leaves the patient rigid and unable to move and communicate. An estimated 25 - 50% of PD sufferers experience an OFF episode at least once per day and up to six times per day, with each episode lasting between 30 minutes and two hours.
- Of the 16 patients treated with APL-130277, 14 converted from OFF to ON with all available doses (10, 15, 20, 25 and 30 mg). Clinically meaningful improvement in motor control occurred as quickly as 10 minutes after administration of APL-130277 and lasted as long as 90 minutes. The maximum mean change from baseline UPDRS III was 18.4, a large clinically important difference. Treatment with APL-130277 was safe and well-tolerated.
- The company plans to advance APL-130277 to Phase 3 development.
CYNAF vs. ETF Alternatives
Other News & PR